search
Back to results

EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Primary Purpose

Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB

Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
EB-101 Surgical application of RDEB wounds
Sponsored by
Abeona Therapeutics, Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Epidermolysis Bullosa focused on measuring Chronic wounds

Eligibility Criteria

6 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Clinical diagnosis of RDEB Age 6 years and older; Willing and able to give consent/assent; if under the age of 18 years, guardian(s) is/are willing and able to give consent; Positive expression of NC1+ amino-terminal fragment of C7 in the skin; Two confirmed RDEB C7 mutations with recessive inheritance patterns (or confirmation that parents don't have any evidence of dominant disease); Able to undergo adequate anesthesia during EB-101 treatment; All women of childbearing potential must have a negative urine pregnancy test and use a reliable birth control method throughout the duration of the study and for 24 Weeks post treatment; On stable pain medication regimen for at least 30 days prior to Screening; Must have at least one wound site that meets all of the following criteria: An area ≥20 cm2 Present for ≥6 months Stage 2 wound defined as an open skin wound with partial thickness loss of dermis that has not extended through the dermis into subcutaneous tissue Exclusion Criteria: Medical instability limiting ability to travel to the study site or undergo EB-101 treatment; The presence of medical illness expected to complicate participation and/or compromise the safety of this technique, such as active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; Evidence or history of immune response to C7 by indirect immunofluorescence (IIF) or enzyme-linked immunosorbent assay; Evidence of systemic infection; Current evidence or a history of squamous cell carcinoma (SCC) in the area that will undergo EB-101 application; Active drug or alcohol addiction; Hypersensitivity to vancomycin or amikacin; Receipt of chemical or biological investigational therapy for the specific treatment of RDEB in the 3 months prior to EB-101 application; Positive pregnancy test or breast-feeding; Inability to properly follow protocol assessments and protect keratinocyte sheet sites as determined by the Principal Investigator; Grade 3 clinical event or laboratory abnormality at Day 0. Abnormalities such as esophageal strictures, anemia, low albumin, and pain/itch are expected in RDEB patients, and these abnormalities will not exclude a patient; Unwillingness or inability to provide 4-biopsies or inability to manufacture patient's keratinocytes for use in EB-101 application.

Sites / Locations

  • Stanford UniversityRecruiting
  • University of Massachusetts Medical SchoolRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

EB-101 Surgical application of RDEB wounds

Arm Description

New or Previously Treated RDEB Patients

Outcomes

Primary Outcome Measures

Safety Endpoint (number of treatment related adverse events (AEs) and serious adverse events (SAEs)
The number of treatment related adverse events (AEs) and serious adverse events (SAEs).
Safety Endpoint (number of patients and wounds that have an infection or any related adverse event.)
The number of patients and wounds that have an infection or any related adverse event.
Safety Endpoint (number of patients and wounds that result in hospitalization (serious adverse event )
The number of patients and wounds that result in hospitalization (serious adverse event [SAE]).
Safety Endpoint (Incidence of squamous cell carcinoma)
Incidence of squamous cell carcinoma
Safety Endpoint
qPCR detection of replication competent retrovirus (RCR) infection in whole blood (detected/not detected)

Secondary Outcome Measures

Full Information

First Posted
January 23, 2023
Last Updated
September 20, 2023
Sponsor
Abeona Therapeutics, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT05725018
Brief Title
EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Official Title
A Phase 3b Study for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) in New and Previously EB-101 Treated Patients
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 2, 2023 (Actual)
Primary Completion Date
August 1, 2024 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abeona Therapeutics, Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate and further characterize the safety of EB-101 (LZRSECol7A1 Engineered Autologous Epidermal Sheets [LEAES]) for the treatment of RDEB wounds in new and previously EB-101 treated patients 6 years and older.
Detailed Description
A Multicenter, open-label, single-arm Phase 3b safety study of one-time surgical application of up to 8 autologous, gene-corrected keratinocyte sheets (EB-101) for the treatment of RDEB wounds in approximately 10-12 patients. Patients enrolled will also contribute biopsies to support manufacturing requirements. Patients will be evaluated at their Day -26 Screening visit, a phone call approximately 14 days after screening, and at Baseline (Day -1) prior to treatment on Day 0. Patients will remain in the hospital, or other suitable medical facility, as determined by the investigator, for observation for up to 5 days (+/- 1 day) following treatment and will be evaluated by phone on Day 14, by telehealth visits on Weeks 4, 8, and 18, and by clinic visits on Weeks 12 and 24. All patients will be followed through 24 weeks post-treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
Keywords
Chronic wounds

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
EB-101 Surgical application of RDEB wounds
Arm Type
Experimental
Arm Description
New or Previously Treated RDEB Patients
Intervention Type
Biological
Intervention Name(s)
EB-101 Surgical application of RDEB wounds
Intervention Description
EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7 Other Names: • LZRSE-Col7A1 Engineered Autologous Epidermal Sheets [LEAES]
Primary Outcome Measure Information:
Title
Safety Endpoint (number of treatment related adverse events (AEs) and serious adverse events (SAEs)
Description
The number of treatment related adverse events (AEs) and serious adverse events (SAEs).
Time Frame
6 months
Title
Safety Endpoint (number of patients and wounds that have an infection or any related adverse event.)
Description
The number of patients and wounds that have an infection or any related adverse event.
Time Frame
6 months
Title
Safety Endpoint (number of patients and wounds that result in hospitalization (serious adverse event )
Description
The number of patients and wounds that result in hospitalization (serious adverse event [SAE]).
Time Frame
6 months
Title
Safety Endpoint (Incidence of squamous cell carcinoma)
Description
Incidence of squamous cell carcinoma
Time Frame
6 months
Title
Safety Endpoint
Description
qPCR detection of replication competent retrovirus (RCR) infection in whole blood (detected/not detected)
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of RDEB Age 6 years and older; Willing and able to give consent/assent; if under the age of 18 years, guardian(s) is/are willing and able to give consent; Positive expression of NC1+ amino-terminal fragment of C7 in the skin; Two confirmed RDEB C7 mutations with recessive inheritance patterns (or confirmation that parents don't have any evidence of dominant disease); Able to undergo adequate anesthesia during EB-101 treatment; All women of childbearing potential must have a negative urine pregnancy test and use a reliable birth control method throughout the duration of the study and for 24 Weeks post treatment; On stable pain medication regimen for at least 30 days prior to Screening; Must have at least one wound site that meets all of the following criteria: An area ≥20 cm2 Present for ≥6 months Stage 2 wound defined as an open skin wound with partial thickness loss of dermis that has not extended through the dermis into subcutaneous tissue Exclusion Criteria: Medical instability limiting ability to travel to the study site or undergo EB-101 treatment; The presence of medical illness expected to complicate participation and/or compromise the safety of this technique, such as active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; Evidence or history of immune response to C7 by indirect immunofluorescence (IIF) or enzyme-linked immunosorbent assay; Evidence of systemic infection; Current evidence or a history of squamous cell carcinoma (SCC) in the area that will undergo EB-101 application; Active drug or alcohol addiction; Hypersensitivity to vancomycin or amikacin; Receipt of chemical or biological investigational therapy for the specific treatment of RDEB in the 3 months prior to EB-101 application; Positive pregnancy test or breast-feeding; Inability to properly follow protocol assessments and protect keratinocyte sheet sites as determined by the Principal Investigator; Grade 3 clinical event or laboratory abnormality at Day 0. Abnormalities such as esophageal strictures, anemia, low albumin, and pain/itch are expected in RDEB patients, and these abnormalities will not exclude a patient; Unwillingness or inability to provide 4-biopsies or inability to manufacture patient's keratinocytes for use in EB-101 application.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Abeona Therapeutics
Email
EB@abeonatherapeutics.com
First Name & Middle Initial & Last Name or Official Title & Degree
Abeona Therapeutics
Email
patients@abeonatherapeutics.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dmitriy Grachev, MD, PhD
Organizational Affiliation
Abeona Therapeutics, Inc
Official's Role
Study Director
Facility Information:
Facility Name
Stanford University
City
Redwood City
State/Province
California
ZIP/Postal Code
94063
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Massachusetts Medical School
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01605
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

We'll reach out to this number within 24 hrs